secwatch.observer — SEC 8-K summary
======================================

Issuer:     LEXICON PHARMACEUTICALS, INC. (LXRX)
CIK:        0001062822
Form:       8-K
Filed at:   2026-02-02T23:59:59+00:00
Accession:  0001193125-26-033793
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 5.03, 3.02, 3.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexicon raises ~$94.6M via public offering and private placements; Invus to hold ~51% post-conversion
--------------------------------------------------------------------------------

- Public offering of 32M shares at $1.30/share raises ~$41.6M gross; underwriters have 30-day option for 4.8M more shares.
- Concurrent private placement: 22.4M common shares to Invus at $1.30 for $29.12M; also 184,366 Series B Convertible Preferred shares at $65 each (~$11.98M) convertible into 9.2M common shares.
- Additional private placement: Invus buys 182,779 more preferred shares at $65 each for ~$11.88M, convertible into 9.1M common shares; total preferred convertible into ~18.3M common shares.
- After conversion of preferred and stockholder approval to increase authorized shares, Invus entities will hold about 51% of outstanding common stock.
- Net proceeds to fund continued R&D of drug candidates and for working capital and general corporate purposes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1062822/000119312526033793/0001193125-26-033793-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1062822/000119312526033793/d32395d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-033793

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer